| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8724368 | Osteoporosis and Sarcopenia | 2017 | 7 Pages |
Abstract
In post-menopausal women and men above 50 years, bisphosphonates remain the mainstay of treatment in GIO. In pre-menopausal women and men below 50 years, bisphosphonates are recommended for those with a prevalent fracture or at very high risk only.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Swan Sim Yeap, Fen Lee Hew, Premitha Damodaran, Winnie Chee, Joon Kiong Lee, Emily Man Lee Goh, Siew Pheng Chan, The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,